Value proposition
STRING tells you what is already known about gene interactions in a universal, literature-based context. Mavatar Discovery shows you what the data reveals in a tissue-specific, condition-aware, analytically rich environment, including interactions that the literature hasn't caught up with yet.
Key differences between STRING and Mavatar Discovery:
Data-driven versus literature-driven
STRING builds its interaction networks primarily from curated literature, text mining, and existing databases. This means it reflects what is already known and published, which introduces an inherent knowledge bias. Well-studied genes and well-characterized pathways are overrepresented, while less-studied genes may appear isolated or poorly connected even if they play important biological roles. Mavatar Discovery takes a different approach. Its networks are built directly from large-scale transcriptomic data: gene co-expression and interaction patterns derived from thousands of real samples. This makes them fully data-driven, capable of surfacing novel interactions that have never been described in the literature, precisely because they emerge from the data itself rather than from prior knowledge.
Context-specific versus universal
STRING provides a single, organism-level network. Whether you're studying gene interactions in the brain, the liver, or the blood, you're looking at the same network. But biology doesn't work that way. The interactions that matter in one tissue are often absent or entirely different in another. Mavatar Discovery builds tissue-specific and cell type-specific networks, reflecting the reality that gene regulatory relationships are context-dependent. A gene pair that is tightly co-expressed in blood may show no meaningful interaction in brain tissue, and the platform captures that distinction rather than collapsing it into a single universal map.
More than just a network
STRING is, at its core, a network visualization and interaction database. Mavatar Discovery starts with the network but embeds it within a full analytical environment. From a single graph, you can move into Patient Stratification, Gene Expression, Cell Type Explorer, Functional Enrichment, Functional Annotation of edges by dataset and Rare Disease, and Drug Target overlays … all without leaving the platform. This means you're not just seeing that two genes interact; you can immediately ask in which conditions that interaction is strongest, which cell types express those genes, what pathways they participate in, and whether either gene is a known drug target.
Traceability back to raw data
Because Mavatar Discovery's networks are built from real transcriptomic datasets, every interaction in the platform can be traced back to the original samples and studies that produced it. This gives you a level of data provenance that literature-curated networks cannot offer. You can see not just that an interaction exists, but which patient cohorts, disease states, and experimental conditions support it.
Rare disease research faces a fundamental challenge: patient populations are small and geographically dispersed, making it difficult to generate statistically robust results from any single study. While important efforts exist to aggregate clinical and patient data, connecting findings at the molecular level across different rare diseases remains a significant gap.
Mavatar Discovery integrates transcriptomic data from thousands of publicly available samples across tissues and conditions, including rare diseases. By placing your rare disease genes into these large-scale networks, you effectively overcome the sample size limitation that constrains most rare disease studies, contextualizing your findings within a much broader molecular landscape than your own cohort could provide.
More importantly, the platform enables cross-disease comparison at the network level. Many rare diseases affect overlapping biological systems: shared pathways, common regulatory hubs, convergent molecular mechanisms. By exploring how gene networks from one rare disease relate to those from related conditions, you can identify common treatment targets that might work across multiple diseases affecting the same biology. A gene that emerges as a hub connecting shared pathways across several rare neurological conditions, for example, becomes a far more attractive therapeutic candidate than one supported by a single underpowered study in one disease.
The tissue-specific and condition-specific nature of our networks is especially relevant here. Rare disease biology is often highly tissue-dependent, and exploring your genes in the appropriate tissue context ensures that the interactions you uncover are relevant to the systems affected and not diluted by signals from unrelated tissues.
In summary, Mavatar Discovery helps rare disease researchers do what is hardest to do in this field: cut through the noise of small cohorts, find real biological signal through large-scale data integration, and identify molecular connections across related conditions that point toward shared therapeutic opportunities.
Mavatar Discovery is a growing platform built for exploration with purpose, evolving weekly to empower researchers to perform comprehensive explorations of the data.
The platform is designed to take you from an initial set of genes or a disease query all the way to actionable biological insights: identifying disease mechanisms, discovering biomarker candidates, uncovering drug-targetable genes, and generating hypotheses grounded in large-scale transcriptomic evidence.
Every tool in the platform, from Functional Enrichment and Gene Expression to Drug Target overlays and cell type-specific networks is there to help you move beyond observation and toward conclusions you can act on in your research, whether that means prioritizing candidates for experimental validation, building a case for a drug repurposing hypothesis, or contextualizing your omics findings within a broader biological framework.
The platform is also continuously evolving. New features, datasets, and analytical capabilities are added regularly, expanding what you can do with each iteration. So, while today's workflow already supports end-to-end analysis from gene query to translational insight, the scope of what Mavatar Discovery can deliver is growing every week.
Performing this kind of multi-layered analysis such as building gene networks, running enrichment, generating heatmaps, exploring single-cell expression, comparing conditions, and assessing druggability would require a bioinformatician proficient in multiple programming languages, statistical frameworks, and visualization tools. Each step would involve separate software, custom scripts, and considerable time spent on data wrangling before any biological interpretation could begin. Mavatar Discovery consolidates this entire workflow into a single interactive platform, empowering researchers to move directly into the biology without the need of coding, tool integration, or computational debugging. The goal is not to replace bioinformatics expertise but to remove the technical barriers so that the focus stays on the science.
Yes, here you can see our case studies: